Budesonide 1264814 224303470 2008-07-08T06:53:33Z VolkovBot 3035831 robot Adding: [[pt:Budesonide]] {{drugbox | IUPAC_name = 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-β,16-α)-pregna-1,4-diene-3,20-dione | image = Budesonide.png | width = 200 | CAS_number = 51333-22-3 | ATC_prefix = A07 | ATC_suffix = EA06 | ATC_supplemental = {{ATC|D07|AC09}}, {{ATC|R01|AD05}}, {{ATC|R03|BA02}} | PubChem = 63006 | DrugBank = APRD00442 | C=25 | H=34 | O=6 | molecular_weight = 430.534 g/mol | smiles = CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C @@]2(O1)C(=O)CO | bioavailability = 100% (but large first pass effect) | protein_bound = 85-90% | metabolism = Hepatic [[CYP3A4]] | elimination_half-life = 2.0-3.6 hours | excretion = Renal, Faecal | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = C | pregnancy_category = | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 --> | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = POM | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_status = | routes_of_administration = Oral, Nasal, tracheal, rectal }} '''Budesonide''' is a [[glucocorticoid]] [[steroid]] for the treatment of [[asthma]], non-infectious [[rhinitis]] (including [[hay fever]] and other allergies), and for treatment and prevention of [[nasal polyp | nasal polyposis]]. Additionally, it is used for [[inflammatory bowel disease]]. It is marketed by [[AstraZeneca]] as a [[nasal]] inhalation with the brand name '''Rhinocort''' (in Denmark, as '''Rhinosol'''), as an oral inhalation with the brand name '''Pulmicort''', and as an enema and a modified-release capsule with the brand name '''Entocort'''. It is also sold in combination with [[formoterol]] (Oxis) in a single inhaler, with the brand name [[Symbicort]]. ==Pharmacology== Budesonide has a high first pass [[metabolism]]. It has efficacy in the terminal [[ileum]] and the right [[Colon (anatomy)|colon]]. Budesonide in comparison with prednisolone has been associated with fewer bone density losses and unlike other corticosteroids has little influence on the hypothalamic-pituitary-adrenal axis which also limit the need of tapering before discontinuation. Overall, it has a lower incidence of systemic manifestations than similar medications. ==Side Effects== Budesonide may cause<ref>[http://www.emedicinehealth.com/budesonide-nasal_aerosol_inhaler/article.htm]</ref>: * nose irritation or burning * bleeding or sores in the nose * lightheadedness * upset stomach * cough * hoarseness * dry mouth * rash * sore throat * bad taste in mouth * change in [[mucus]] color In addition the following should be reported: * Immediately if difficulty breathing or swelling of the face * white patches in the throat, mouth, or nose * irregular menstrual periods * severe acne * rarely, behavioral changes -- when these do occur, they seem to mostly affect children. For citation, see reference above. ==Recall== Pulmicort inhalers were recalled in 2002 because there was concern that they may not always have provided the full dosage. ==External links== * [http://www.asthma-and-you.com Latest Asthma News!] * [http://www.astrazeneca-us.com/pi/entocortec.pdf FDA Label (PDF)] * [http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a601030.html National Institute of Health's Medline about Budesonide] {{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} {{Nasal preparations}} {{Asthma_and_copd_rx}} {{Corticosteroids}} [[Category:Glucocorticoids]] [[Category:Asthma]] [[de:Budesonid]] [[hr:Budezonid]] [[it:Budesonide]] [[hu:Budezonid]] [[nl:Budesonide]] [[pl:Budezonid]] [[pt:Budesonide]] [[zh:布地奈德]]